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a b s t r a c t
In the light of a number of serious incidents in the UK resulting from accidental overdoses of methotrexate,
this study investigated how the design of methotrexate packaging can influence patient safety, and aimed
to collect evidence to provide a basis for the development of new concepts for revised designs by the
pharmaceutical industry. The research found that patients using methotrexate experience a number of
difficulties in using their medicines packaging, and as a result, resourcefully adopt a variety of ‘‘coping
strategies’’ whichmay increase the risk of dosing errors. By investigating both the practice ofmethotrexate
users, and the design of the system that supports methotrexate use, additional problems were observed
across the healthcare system, meaning that the function of medicines packaging in ensuring safety may be
even more critical than first suspected. As a result of this research the National Patient Safety Agency
responded with a UK-wide programme of work to improve safety for patients, and continues towork with
the pharmaceutical industry to develop more user-friendly packaging and labelling.
! 2010 Elsevier Ltd. All rights reserved.
1. Introduction
1.1. The packaging and labelling of medicines in the UK
Across the UK medicines are usually packaged in two types of
container: in bottles with push-down-and-turn closures (a type
of ‘‘child-resistant closure’’ or CRC) and in blister packs, consisting of
one or more blister strips, each containing a number of tablets.
Labelling provides the identity of the medicine and the patient it is
intended for, its strength, dose, route and contraindications. Pack-
aging and labelling, therefore, play a crucial role in housing and
protecting medicines and in conveying a range of information to
users. However, themedicineswithin these containers are becoming
ever more diverse, complex and potent (Audit Commission, 2001),
increasing the potential for harm and the corresponding need for
safemanagement ofmedicines. Yet, research has shown that around
half of all patients in the UK are not adherent to their medication
regimen (Wright, 1993) and evidence abounds of medicines-related
harm both in hospital and community care (DH, 2004).
There are many reasons why substandard adherence can occur
(Marinker and Shaw, 2003), but poor design of the packaging or
labelling of medicines is known to be a noteworthy contributing
factor. Through its Web site, the Institute of Safe Medication
Practices (ISMP) in the US provides many examples of unclear and
confusing designs, which have led to the potential for error or even
deaths of patients. Indeed, based on figures from the ISMP, Kenagy
and Stein have estimated that as many as 10,000 patients are
injured or killed each year due to labelling and packaging related
issues (Kenagy and Stein, 2001).
More specifically, many studies have reported on a variety of
such issues experienced by patients, resulting in outcomes ranging
from mild inconvenience to serious medical complications or even
death. These problems include difficulties in opening containers
(Atkin et al., 1994; Beckman et al., 2005; Clark, 2002; Donaghy and
Wright, 2003; DTI, 1999; Thwaites, 1999), mix-ups between
medicines due to similarity in appearance (BMJ, 2003; Cramer,
1998; DH, 2004; Toogood, 2002), problems with reading and
understanding labelling and instructions (Bernardini et al., 2001;
Bernardini et al., 2000; Braus, 1993; Kalsher et al., 1996; Moisan
et al., 2002; Sansgiry et al., 1997) and difficulties remembering key
information about their medicine (Kerr et al., 2003). Most studies
suggest that problems are commonplace, particularly for older
users of medicines.
Successful use of the packaging and labelling of medicines
requires a degree of both physical (visual and muscular) and
cognitive ability to perform tasks such as opening containers and
reading and understanding instructions. Not only may the indi-
vidual tasks, such as gripping, squeezing or turning, be difficult for
patients, but combinations of two or more of these actions may
require to be performed simultaneously, meaning that opening
* Corresponding author.
E-mail address: jrw38@cam.ac.uk (J. Ward).
Contents lists available at ScienceDirect
Applied Ergonomics
journal homepage: www.elsevier .com/locate/apergo
0003-6870/$ – see front matter ! 2010 Elsevier Ltd. All rights reserved.
doi:10.1016/j.apergo.2009.12.005
Applied Ergonomics 41 (2010) 682–694
packaging can create difficulties in coordinating these movements
(DTI, 1999).
One of the reasons for these difficulties is the fact that a patient’s
abilities can be drastically reduced by their medical condition, as in
the cases of rheumatoid arthritis on physical strength and dexterity,
and uncontrolled diabetes on visual ability through diabetic reti-
nopathy. In addition, the side-effects of the very medication they
are taking can compromise adherence, for example by inducing
forgetfulness and hence reducing a patient’s ability to take their
medicine according to their plan of care. Difficulties in using
medicines can also be particularly pronounced for older users due
to the decline in physical and cognitive ability that is associated
with the ageing process (Cramer, 1998). Yet it is these older people
who are the heaviest users of medicines; in the UK four out of five
people aged over 75 take prescribed medicines (DH,1998), and 60%
of prescriptions in England were dispensed to men and women
aged 60 and over in 2007 (The Information Centre, 2008).
1.2. The packaging and labelling of methotrexate in the UK
In light of the types of problem illustrated so far in this paper,
the design of the packaging and labelling of a medicine called
methotrexate has been under examination by the National Patient
Safety Agency (NPSA), a bodywhichwas formed to assess and assist
improvement in patient safety in the UK’s National Health Service
(NHS). When taken at the right frequency and dose, methotrexate
is a safe medicine. However, through analysing UK records over
a 10-year period, the NPSA identified 137 incidents associated with
methotrexate tablets, which led to some 25 deaths and 26 cases of
serious injury due to unintentional overdoses of the drug (NPSA,
2003). It was suspected that, in some of these cases, poor design of
the packaging and labelling of methotrexate could have contrib-
uted to the error. Consequently, the NPSA funded a programme of
research to determine how and why packaging and labelling might
contribute to such errors and how they might be reduced or
removed in the future. This research formed one of three, parallel,
NPSA studies, aimed to improve safety associated with the use of
methotrexate. The others involved the development of a new
patient treatment diary and modification of IT systems in General
Practitioners’ (GP) surgeries and community pharmacies. This
research is now concluded, and a summary of findings and rec-
ommended practice for the NHS can be found through the NPSA’s
web site (www.npsa.nhs.uk).
Almost no published evidence is available on the demographics
of methotrexate users and their use of methotrexate in the UK.
Harris reports that annually around 50,000 patients receive oral
methotrexate treatment from the NHS in England and Wales
(Harris, 2005). The vast majority of these are rheumatological and
dermatological patients. Given the aforementioned effects of
arthritis on strength and dexterity, this maymean that the majority
of methotrexate users may experience a reduction in their ability to
open medicines containers.
At the time of this study (2003), methotrexate in the UK was
normally administered to rheumatology and dermatology patients
utilising tablets of 2.5 mg and 10 mg, being packaged loose in packs
of 100 or in blister packs of 28. Methotrexate has a number of
characteristics which underscore the importance of appropriate
dosing by patients. Its dose is highly patient-specific, ranging
typically from between 5 and 25 mg. However, the frequency with
which methotrexate is taken is unusual; for rheumatology and
dermatology patients methotrexate is normally taken once a week,
rather than on a daily basis like most medicines. Indeed, of the
13,000 medicines licensed for use in the UK, only six are taken on
a weekly basis (Adcock, 2004). Methotrexate can also be classed as
a narrow therapeutic index drug, meaning that it is very important
for the correct dose to be given, with little room for error. Frequent
blood monitoring is therefore required to ensure that an appro-
priate dose is given to the patient.
2. Study aims
Given the potential for both inconvenience and serious error for
patients, the characteristics of methotrexate and its users under-
score the importance of suitable packaging and labelling design.
The research, therefore, aimed to investigate current practice in the
UK healthcare system with solid oral medicines (i.e. tablets), with
a focus on the experiences of rheumatology and dermatology
patients in using methotrexate. To realise this aim, the following
objectives were formed:
1. Investigate patients’ practice in using solid oral medicines and
determine how and why patients currently take, and some-
times fail to take, the right dose of their medicines.
2. Develop recommendations as to how the safe use of medicines
by patients can be encouraged through the design of medicines
packaging and labelling.
3. Present problems associated with packaging and labelling
design to manufacturers of methotrexate, to encourage new
developments, where necessary.
However, before any new developments are integrated into the
healthcare system (including the patient’s home), it is important to
consider their interaction with the other elements of the system.
Without such a ‘‘systems’’ understanding, newdesigns are unlikely to
be optimal as they may inadvertently create further difficulties
(Clarkson et al., 2004; Carayon et al. 2006). Indeed, in addition to the
packaging and labelling of methotrexate, a number of mechanisms
help toensure the safeandsuitabledeliveryof thisdrug to thepatient.
From patient assessment before methotrexate is given, to blood test
monitoring, much information is collected, analysed and transferred
between a number of stakeholders, often through a ‘‘shared-care’’
arrangement, governed by a shared-care protocol. These set out
responsibilities for the patient’s care, between the GP (e.g. for moni-
toring blood tests), hospital (e.g. for monitoring the patient’s general
progress) and patient (e.g. for reporting side-effects).
Given the need for a systems understanding, a further objective
was formed:
4. Investigate the healthcare system associated with metho-
trexate packaging and labelling and determine where it can fail
to support patient safety.
3. Research methods
The research reflected the need for a systems understanding by
utilising a number of different research methods to investigate
practice across primary and secondary care, and in the patient’s
home (Buckle et al., 2006; Clarkson et al., 2004).
To investigate the healthcare system, healthcare professionals
from the NHS were interviewed using unstructured interviews.
Maps were developed of the delivery process of methotrexate, from
manufacturer to patient, and the healthcare system surrounding
this process. The maps were used to support two risk analysis
sessions with healthcare practitioners, to identify ‘‘risky’’ areas of
the healthcare system.
Patients’ practice was investigated after receiving ethics
approval from the Local Research Ethics Committee. Semi-struc-
tured interviews took place in their homes and patients were
videotaped as they opened various types of medicines packaging.
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Patients were encouraged to discuss any problems they had in
using their medicines and to describe their thoughts during the
observational exercise.
Based on the findings, basic design requirements for future
packaging and labelling were developed. These formed the basis for
the development of a number of design ‘‘concepts’’. A paper-based
assessment was also conducted, in the form of a ‘‘design exclusion
assessment’’ which investigated the degree to which current
designs of packaging and labelling exclude patients from using
them. The findings from the research and the design concepts were
presented to manufacturers of methotrexate packaging and label-
ling, with a view to encouraging further improvements for users.
3.1. Interviews
12 patients and 10 healthcare professionals were interviewed,
either face-to-face or by telephone. The characteristics of these
interviews are summarised in Table 1.
After receiving ethics approval, patients were recruited through
reviews of GP-practice records of patients using methotrexate,
which were conducted by GPs and practice managers at two
practices in the UK. An additional patient was recruited through
their consultant, in a similar manner. Patients were approached by
letter from their GP/consultant, which included an information
sheet which explained the details of the study. Patients replied to
the researchers if they wished to take part. Primary Care Trust
(community healthcare) R&D approval was obtained for the
research with patients. NHS Trust R&D approval and honorary
research contracts were obtained for the research with NHS
professionals. All participants provided their consent before inter-
views or observations began.
Questions were developed by consulting a range of literature,
including government and company reports, journal articles and
web sites. These provided an indication of the types of problems
that were likely to occur, although questions remained sufficiently
open to identify other areas of need, in addition. The semi-struc-
tured interviews with patients covered patient demographic
details, a review of the types of medication theywere taking, details
of their use of medicines (including their history of taking metho-
trexate) and any problems they might have experienced, both
when first prescribed methotrexate and more recently.
The interviews with healthcare professionals were concerned
with the nature and frequency of problems associated with meth-
otrexate in the healthcare system, and the structure of this system.
Healthcare professionals were identified through opportunity and
snowball sampling. 17 interviews and discussions were conducted
individually with 10 healthcare professionals, working in different
areas of the NHS. Given the size of the study and the variability in
NHS practice (HMSO, 2000), the exercise was intended to highlight
local working practice, and to act as a first step towards under-
standing methotrexate use in the UK.
In addition, the physical (‘‘reach & stretch’’, ‘‘dexterity’’ and
‘‘seeing’’) and cognitive (‘‘thinking’’) capabilities of patients were
assessed against capability scales developed by Martin et al.
(Martin et al., 1988). To do this, patients were read descriptions of
tasks requiring various levels of cognitive or physical ability (e.g.
‘‘cannot count well enough to handle money’’ and ‘‘has difficulty
wringing out light washing or using a pair of scissors’’) and were
asked to agree or disagree whether each was an accurate descrip-
tion of their level of ability.
3.2. Observations
Observations were used to clarify and supplement the data
collected in the interviews. Patients were observed as they used
(opened and closed packages, extracted and picked up tablets)
a variety of different types of packaging, including:
! A bottle with an ‘‘easy’’ push-down-&-turn CRC (approximate
dimensions: top diameter¼ 28 mm, ribbed gripping section on
top¼ 16 mm tall, bottle diameter¼ 32 mm, bottle
height¼ 48 mm; requiring an approximate 2 kg ‘‘push-down’’
force and 0.5 Nm torque to open).
! A bottle with a ‘‘difficult’’ push-down-&-turn CRC (approximate
dimensions: top diameter¼ 28 mm, ribbed gripping section on
top¼ 16 mm tall, square-shaped bottle base¼ 33 mm
# 27 mm, bottle height¼ 48 mm; requiring an approximate
3 kg ‘‘push-down’’ force and 1 Nm torque to open).
! A blister pack, containing three blister strips and an informa-
tion leaflet, tightly packed in a box, as provided by the
manufacturer.
! A bottle with a double-walled squeeze & turn closure.
Both the CRCs were typical of those provided by community and
hospital pharmacies in the UK. Given the cytotoxic nature of
methotrexate tablets, and the dangers of overdose, patients were
presented with blister packs containing low-risk tablets such as
vitamins and homeopathicmedicines, after review by a pharmacist.
The difficulty of opening the bottles with a push-down-&-turn
CRC was assessed through recording comments from patients who
were asked to ‘‘think aloud’’ during the exercise. In addition,
through analysis of the videos, the first author measured the length
of time it took for patients to open these containers. Patients were
first allowed to familiarise themselves with the container, and the
timing was taken from the moment the patient first applied
a pushing or turning motion to the CRC until it was separated from
the neck of the bottle.
3.3. Process mapping and risk analysis
Through the interviews with healthcare professionals and
through perusal of a number of shared-care protocols, two maps
Table 1
Characteristics of the interviews with patients and healthcare professionals.
Interviewee No. of interviewees Type of interview
Patient 12 11 face-to-face semi-structured interviews (11 patients)
1 telephone semi-structured interview, for patient’s personal reasons (1 patient)
General Practitioner 1 5 face-to-face unstructured interviews (1 GP five times)
Community pharmacist 2 2 face-to-face unstructured interviews (2 pharmacists)
1 brief discussion (1 pharmacist, as a follow-up interview)
Hospital pharmacist 3 (at 2 hospitals) 2 face-to-face unstructured interviews (2 pharmacists)
1 telephone unstructured interview (1 pharmacist)
Specialist nurse 2 (at 2 hospitals) 1 face-to-face unstructured interview (1 nurse)
1 telephone unstructured interview (1 nurse)
Clinical directors 2 (1 at 1 hospital and 1 at NHS regional level) 3 face-to-face unstructured interviews (1 director three times)
1 telephone unstructured interview (1 director)
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were developed of the healthcare system regarding methotrexate.
The maps were reviewed by a GP and a hospital-based clinical
director (who was also a practising pharmacist). Modifications
were made to the maps until agreement was reached on the
completeness and accuracy of their content. Subsequently, the
maps were used to form the main input to two risk analysis
sessions, involving the same healthcare professionals, to identify
the areas of the healthcare system that provided the greatest
concern in the safe use of methotrexate. These participants were
selected due to their complementary knowledge of different
sectors of the healthcare system, their considerable experience of
working in the NHS (and in particular their exposure to metho-
trexate-related problems in their respective workplaces) and their
willingness to provide several hours of their time.
Two differing risk analysis methods were chosen to maximise
the chances of identifying risks. The first analysis consisted of
a HAZOP study. A typical HAZOP study is described below:
1) It is common to start with a description of the system in the
form of a process map, showing its intended functions. The
chemical production industries, where HAZOP has been used
traditionally, often use ‘‘piping and instrumentation’’ diagrams,
which show the interconnections of equipment. In a traditional
HAZOP, each function is analysed in turn, in order to provide
input to what tends to be a very systematic and comprehensive
analysis.
2) Deviations from each function are considered by applying one
or more ‘‘guide words’’ to each function. Guide words such as
‘‘No’’, ‘‘Less’’, ‘‘More’’ and ‘‘Other’’ can be applied, to determine
how each function might deviate – i.e. to identify possible
failures in the system. If the deviation ismeaningful, then this is
recorded. For example, considering the flow of a chemical,
a potential deviation from the normwould be ‘‘More’’ chemical.
Another might be ‘‘Other’’ chemical.
3) The consequences, causes and any suggested actions for each
deviation are recorded. Each type of deviation can be given
a risk score and can then be used to judge whether the system
offers a satisfactory level of risk, or help to prioritise this sug-
gested action. The risk score (Risk Priority Number – RPN) can
be calculated by taking the product of thee risk components:
the likelihood (L), impact (I) and detectability (D) (ease of
detection) of each deviation.
In the case of the methotrexate HAZOP, the two process maps
depicted the intended functions, as described in Step 1. The RPNs
were calculated from a simple three point scale for each risk
component (1¼ low, 2¼medium, 3¼ high for Likelihood and
Impact; with reverse scoring for Detectability since it is a desirable
rather than undesirable characteristic), since the healthcare
professionals felt that it was difficult to define precise values.
A HAZOP study was deemed to be a suitable risk analysis
method because the process maps considered flows of materials
and information in a similar way to the flows of chemicals or
materials in the process industries, and the purpose of the analysis
was to investigate how the system might fail to perform as inten-
ded. The HAZOP provided the opportunity to assess the process in
a systematic fashion, through structured thinking by using guide
words, and how the system might introduce errors.
After the HAZOP study was conducted, the research team
re-reviewed the results from the interviews and observations
with patients, the interviews with healthcare practitioners and
the process maps. By considering each setting in healthcare in
turn (e.g. home, GP practice, etc) and brainstorming for risky
situations, a number of ‘‘risky scenarios’’ were identified by the
research team, in the form of a ‘‘risky scenarios study’’. The
outputs from the HAZOP study were also added to the list of risky
scenarios.
Next, a second risk analysis meeting was arranged with the
healthcare professionals, for them to assess the risk of each
scenario. In this case the same three risk components were scored
for each risky scenario, taking the likelihood of occurrence of the
scenario, the severity of harm and the ease of detecting the failure.
Lastly, an RPN was calculated.
This was different from the HAZOP, in that it was led by location
of treatment and was conducted through a free-form analysis
of failure modes, rather than relying directly on the structure of
a diagram. It was anticipated that the combination of the rigour of
a HAZOP and the more free-form structure of the risky scenarios
study would be complementary.
3.4. Design exclusion assessment
Design exclusion occurs when choices made in the process of
designing a product result in a design which cannot be used
effectively. Given the anticipated problems that users of metho-
trexate would experience, a design exclusion assessment was
therefore carried out.
Quantitative design exclusion assessment, as described by
Clarkson et al. (Clarkson et al., 2003), focuses on evaluating the
number of people who are likely to experience difficulties in using
a product. The first step in examining any interaction is to expand
the use scenario (i.e. the process of use within a given context) into
its component tasks to enable a systematic assessment to be per-
formed. As with all studies of this type, there are many possible
interaction paths, so assumptions have to be made about the
context of use. For example, it was assumed for this study that the
methotrexate to be used was stored in a location that was easy to
reach, and so the patients’ abilities to reach and stretch were not
assessed. Similarly, it is assumed that a use scenario, such as using
a standard bottle with a CRC, requires a specific number of tasks. To
use medication in a standard bottle with a CRC, for example, the
patient must read and understand instructions, open a CRC and
pick up a small tablet.
In summary, the demands made by the product on the user for
each task are estimated. The number of people unable to meet such
demands are then evaluated, where the demands are expressed in
terms of the user capability required to interact with the product,
according to scales developed by Martin et al. (Martin et al., 1988)
and adapted for use in product assessments by Clarkson et al.
(Clarkson et al., 2007). The total number of people excluded from
the interaction can be estimated by taking the maximum demands
made by the product during the complete interaction. The levels of
exclusion are calculated from the Office of National Statistics (ONS)
1996/7 Disability Follow-up to the Family Resources Survey
(Grundy et al., 1999; Semmence et al., 1998).
3.5. Developing design requirements and concepts
Design requirements were developed by the researchers
through a review of the nature and frequency of problems expe-
rienced by patients and practitioners in the healthcare system. As
these requirements were to be used by professional designers to
develop concept designs, a brief list was produced to encourage
broad-ranging designs and to ensure that the participants in the
design workshop were not overloaded.
Subsequently, using the requirements, design ‘‘concepts’’, were
developed through a workshop, whose members included those
from various backgrounds such as general engineering design,
healthcare engineering design, packaging design and marketing.
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Several days before the workshop began, designers were sent
a briefing sheet, which outlined the background of the research and
the objectives of the study. All participants read the sheet. The
workshop began with a short presentation, which again outlined
the background of the project and highlighted the key problems
identified during the research, including the healthcare system-
related observations and those directly related to medicines pack-
aging and labelling. To encourage further thought about the design
problem, the designers were asked to develop their own design
requirements based on what they had learned through the
presentation. With a view to assisting future design changes, the
findings from the research, showing the problems that patients and
stakeholders experienced, were presented to the manufacturers of
methotrexate in the UK. Videos, photographs, quotations and
explanation from the researchers were used to highlight these
difficulties.
4. Results
4.1. Interviews with patients
Five patients at one GP practice agreed to take part in the study
and six at the other. An additional patient was recruited through
their consultant at their local hospital; giving a total of 12 patients
(11 female, 1 male), aged 59.8 years on average (range 17–82;
standard deviation 19.2). Nine out of the 12 patients had rheuma-
toid arthritis, two had psoriatic arthritis and one had another
medical condition. Patients assessed against the ONS data were
found to experience few major problems in any of the categories of
physical strength, dexterity, visual ability or cognitive ability.
The review of patients’ medicines showed that they were
taking regularly on average 7.7 prescription-only medicines (range
2–13; standard deviation 4.2). Five patients took 10 or more
prescription-only medicines. At the time of contact with the
researchers, approximately half of the patients had their metho-
trexate delivered in bottles with CRCs and half in blister packs,
although patients explained that the container often varied from
one type to the other. Patients also highlighted the fact that the
appearance of the container varies, according to the pharmacist
they attend, and from one purchase of their medicine to another.
There was a wide variation in how long the patients had been
taking methotrexate, ranging from four months to 20 years, with
an average of 6 years.
Three of the patients had assistance in preparing/taking their
medicines, either from a friend or spouse. One of the key reasons
given for this was that their assistant was judged by them to be
better at opening the medicines containers.
When examining the patients’ medicines containers, a number
of observations weremade. Blister strips can appear similar or even
identical to those from other manufacturers, which may contain
different medicines, particularly when viewed from the opposite
side to the foil wrap, which is often unmarked and made of an
opaque, white plastic. In addition, it is fairly routine for pharmacists
to re-pack blister strips from a manufacturer’s blister pack into
a white generic pharmacy box. Many different medicines may be
issued to patients in such boxes, as illustrated in Fig. 1, and the
labels on the boxes can also appear similar at a glance.
Several issues were noted with pharmacy bottles in relation to
their appearance. Firstly, such bottles can be round, rectangular or
square in cross-section. This means that, when viewed from the
front of the bottle, important information can be hidden due to
the way in which the label is wrapped around the sides of the
container. Secondly, particularly on smaller bottles, labels can be
misaligned or too large for the bottle and consequently distorted
so that information is difficult to read, as illustrated in Fig. 2,
where the word ‘‘METHOTREXATE’’ and the reference to the
strength of each tablet have been distorted. Thirdly, as with blister
packs, medicines may be repacked into generic pharmacy bottles,
and the containers can appear similar to each other, as shown in
Fig. 1.
Continuing the theme of similarity of packaging, almost all of
the patients were prescribed folic acid as well as methotrexate.
Folic acid and methotrexate tablets are similar in appearance, as
illustrated in Fig. 3.
To examine actual practice, patients were asked whether they
had mixed up their medicines in the past. Although most patients
felt this would be difficult, three had done so; two with metho-
trexate and folic acid. One of the patients had reached the stage of
ingesting the wrong tablets, on one occasion. Three patients
commented, without prompting, on the similarity between
methotrexate and folic acid containers and tablets.
Given the significant number of medicines that patients were
receiving, it was common for patients to store all their medicines
together in a single container, such as an ice-cream tub or shoe box,
as shown in Fig. 4.
Patients were also asked whether they stored their medicines in
the original containers. Three patients transferred their metho-
trexate tablets into another container because the original was
awkward or too difficult to open. For example, upon receiving
a new bottle or blister pack from the pharmacy, one patient would
remove all tablets in ‘‘one session’’ and place them in an old
methotrexate bottle with a CRC. The interviewee reported that the
old methotrexate CRC (some seven years old) was much easier to
open, as the CRC had become very worn over the years.
Seven of the patients expressed concern over the difficulties
they experienced when opening bottles with push-down-and-turn
CRCs. Patients experienced pain and/or frustration when opening
containers, as illustrated by the following quotations from three
different patients:
‘‘[It’s] physically [painful], just twisting it in your fingers.’’
‘‘Some are really a nightmare. The new ones are a nightmare.’’
‘‘When I had the bottles I could hardly ever, ever, ever open
them because of the lock on themwhen you have to press down
and turn. To me it just seemed completely bizarre why you’d
give someone with arthritis a bottle that is really hard to open.
It’s kind of like saying: ‘here’s your medication. if you can get
to it!’.’’
Although all patients said they were able to use blister packs,
many found them awkward or ‘‘tedious’’ to use, especially if they
hadmany tablets to extract. The following quotations are indicative
of the problems patients experienced:
‘‘I find blister packs tedious. They’re slightly easier than screw
caps. But when you have to take six, it’s fairly tedious pressing
out six pills.’’
‘‘I must admit that some of the blister packs are really difficult to
get the tablets out of.’’
‘‘It’s a bit annoying pushing the pills through because it’s a bit
fiddly.’’
As a result of their difficulties in using medicines containers,
patients explained that they adopted a variety of coping strategies,
including:
! Using scissors to cut the blister foil to ease removal of the
tablets from the blister strips.
! Transferring tablets from one container to another that was
easier to open.
! Using tools such as nutcrackers or jam jar grips to open bottles
with CRCs.
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! Not fully re-closing the CRC, to ensure that it was opened more
easily the next time it was used (three patients), meaning that
its purpose was defeated.
In addition, through the interviews, the researchers identified
a number of areas in the healthcare system as having the potential
to compromise patient care:
! A lack of information provided to patients by various parties,
including pharmacists (who may not provide information
leaflets to patients because the manufacturer does not provide
them with a sufficient number, and copying is not allowed) or
other healthcare professionals (for example, the supply of
information sheets about methotrexate use for arthritis
patients was sporadic).
! Conflicting dosing information being registered in different
locations (e.g. on a patient’s records at the GP’s practice, at their
local pharmacy, at hospital and the labelling on the patient’s
medication), often due to the frequency with which the
patient’s dose will change, particularly when early in their
treatment when the most appropriate dose is being deter-
mined through monitoring and re-prescribing.
! Due to the quantity of tablets supplied, some patients may only
rarely need to attend the surgery/pharmacy, meaning that the
opportunity for a healthcare professional to identify any dosing
error presents itself infrequently.
! There are many areas where the blood monitoring process can
fail to identify improper methotrexate dosing (e.g. failure to be
issued with appropriate literature to record key information
such as methotrexate dose and next appointment times, failure
by the patient to attend appointments for monitoring and
failures in taking prompt action as a result of adverse effects
being discovered through blood testing).
4.2. Observations of patients
All of the 11 patients who were interviewed in their homes
agreed to be videotaped as they opened the containers. The
observations complemented the results from the interviews since
they allowed the researchers to see at first hand the scale and
nature of the difficulties that patients experienced, and the various
strategies they used to try to open the containers, including using
tools, table tops to provide support and different hand gripping
arrangements. The results from the difficulty assessment of
patients opening bottles with CRCs are tabulated in Table 2, with
added salient comments from the patients.
The observations added weight to the results from the inter-
views: opening the bottles with CRCs presented a significant
challenge to the patients, with nearly half of the patients being
unable or unwilling to open the container with the ‘‘difficult’’ CRC.
The 11 patients were also observed as they opened blister packs
and handled tablets. The use of blister packs requires a number of
sub-tasks to be performed, and observations from each of these are
described in Table 3.
Fig. 1. At a glance, pharmacy containers can appear similar (patient details have been removed and company details have been blurred).
Fig. 2. The arrangement of labelling around the sides of the container (patient details
have been removed and company details have been blurred). Fig. 3. Folic acid (left) and methotrexate (right) tablets (scale in cm).
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To further investigate their ability to use medicines, the patients
were asked to pick up a small tablet, which was spherical in shape
and approximately 3 mm in diameter. Two patients had difficulty
with this task. In at least one case, the problemsmight be explained
by the patient’s medical condition, which made it difficult to form
a fist-shape, which is necessary to pick up the tablet.
In assessing the ease of opening of the double-walled squeeze &
turn closure, patients experienceddifficulties inboth identifying how
to open the container and in opening it. Ten patients attempted the
task (onedeclined since she believed itwould be too difficult for her).
The majority had not attempted to open such a container before.
Seven out of the ten patients took over a minute in their attempt to
open this CRC andmuchof this timewas generally spent in fruitlessly
attempting to turn the top without first squeezing the ends. Two
patients took nearly three minutes each to open the closure. One
succeeded and the other gave up after this period of time. Three
patients commented that it was difficult to notice or read the
instructions since theywere embossedon the closure andnoattempt
had been made by the manufacturer to use contrasting colours.
Once they had identified how to open the container, four
patients were unable to provide sufficient force to squeeze the top
to release the child-resistant mechanism and hence were unable to
remove the closure.
4.3. Interviews with healthcare professionals
The interviews highlighted a number of potentially problematic
areas in the NHS where safety of patients may be compromised
under particular circumstances. These included:
! Significant delays in communications between hospital and
community care.
! Critical information being lost between different nodes in the
healthcare system, e.g. between practice receptionists and GPs
or between GPs and the practice nurse.
! Different healthcare professionals working at different times,
meaning that direct communication between them can be
problematic, particularly at weekends.
! Incorrect information being passed between healthcare
professionals (including an example of a GP being informed by
a consultant that methotrexate should be taken once a day, not
once a week).
! A lack of availability of the procedures concerning giving
methotrexate in an NHS hospital, leading to the potential for
healthcare professionals to be under-informed.
! Through contact with specialist nurses, further examples of
patients’ errors in taking methotrexate, including several cases
where patients had taken four times the correct dose, due to
mix-ups between the 10 mg tablets and the 2.5 mg tablets.
! The default setting on the GPs’ prescribing software being
a once-daily dose, meaning that it was not difficult to mis-
prescribe methotrexate to rheumatology/dermatology patients
at a lethal frequency.
4.4. Process mapping and risk analysis
Both process maps showed various job types and entities con-
nected with the provision and management of methotrexate,
ranging from GPs and consultants to blood test results and data-
bases containing patient-related information. Each was connected
by arrows depicting flows of information and materials between
the different stakeholders.
The first map is shown in Fig. 5, which is based on an amal-
gamation of different shared-care arrangements from around the
UK and therefore shows a variety of ways in which care can be
provided. For example, whilst a GP might normally be informed to
prescribe methotrexate by a consultant, on occasion the consultant
might prescribe methotrexate directly. Given the size of the study,
however, this should not be considered to be an exhaustive
representation of the arrangements across the NHS, and has been
included as an illustration in particular to help the reader
Fig. 4. A typical storage method for patients using multiple medicines.
Table 2
Results of assessment of patients opening bottles with CRCs (n¼ 11).
Patient
ID No.
Time to taken to
remove CRC from
bottle with ‘‘easy’’





Time to taken to
remove CRC from bottle
with ‘‘difficult’’ CRC (s).
X¼ did not wish to
attempt. N¼ attempted
but could not open
container.
Patient’s comments
1 6 14 ‘‘Quite a struggle’’
(difficult container)
2 N X ‘‘No I can’t do it.
there’s not enough
power in my hands’’
(easy container)
3 3 5 –
4 10 13 ‘‘It hurts my fingers’’
(difficult container)
5 24 N ‘‘I’d have to get help
on that one’’ (difficult
container)
6 N X ‘‘No, I couldn’t do it’’
(easy container)
7 7 N ‘‘It really is child-
proof and age-proof’’
(difficult container)
8 3 19 ‘‘Oh gosh. That was
quite a difficult one’’
(difficult container)
9 N X ‘‘No, too difficult’’
(easy container)
10 5 5 ‘‘Ones like these I
really have to press
down.’’ (easy
container)
11 18 2 ‘‘It’s very hard.’’ (easy
container)
Totals 3 patients unable to
open ‘‘easy’’
container. Average
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appreciate the form of the two process maps. The secondmap is not
displayed in this paper, since it was an extension of the first and
contained similar content but at a greater level of detail; focusing
on the blood test monitoring process.
The maps highlighted the complex and variable nature of the
healthcare system that supports the delivery of methotrexate to
patients, and showed many interactions between a range of
stakeholders, and consequently suggested numerous areas where
problems could occur.
For the HAZOP study, using the maps as prompts, the GP and
clinical director identified a number of deviations from intended
practice, and subsequently calculated a risk score for each.
Ideally, every link between the nodes would have been inter-
rogated in turn with a pre-defined list of guide words. However,
given the participants’ time restrictions, it was not possible to
analyse all links systematically, and participants selected links for
consideration in the HAZOP study.
The HAZOP results produced a range of high, medium and low
risks. High andmedium risks included the danger that the patient’s
records (either a blood record card, medical record, prescribing
record or drug chart) may not be updated when information is
added or changed; that records may not be legible and that infor-
mation provided to patients may be unclear, incorrect or incom-
plete. An excerpt from the HAZOP results is shown in Table 4.
Under the ‘‘Risky Scenarios’’ study, 47 scenarios were identified
by the researchers, across a range of healthcare settings, including
the GP practice, home, community and hospital pharmacies and
hospital wards. The list was prepared in a tabular format and
reviewed by the clinical director (the GPwas unavailable) and a risk
score (RPN) was added to each scenario. The top five risky scenarios
are shown in Table 5.
A complete set of risk analysis results is presented byWard et al.
(Ward et al., 2004).
4.5. Design exclusion assessment
The abilities of the patients were assessed, in terms of (1) reach
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Fig. 5. Shared-care arrangements for methotrexate supply in the NHS.
Table 3
Observations on patients’ difficulties and coping strategies when accessing medicines from a blister pack (n¼ 11).
Sub-task Observations
Opening box No difficulties for patients
Removing blister strips Three experienced difficulties. One patient shook the box until a strip was sufficiently exposed to be pulled out with a finger and thumb.
Pushing out tablets Three experienced difficulties. Two pierced the foil on the back of the blister strip with a fingernail to facilitate removal of the tablets. One
patient took 15 seconds to remove a single tablet.
Replacing contents
back in box
Five experienced difficulties. Replacing the contents was found to be more difficult when fewer tablets were present in the strips: in such
cases the strips were more flexible and were sometimes misshapen due to wear and tear, meaning that more precise manipulation was
required to return them into the box. Patients’ ease of replacing the contents was also affected greatly by the method that they employed.
Some patients assembled the contents outside the box and then replaced them all at once, whereas others returned the contents in
a piecemeal fashion, which appeared to be more problematic when space in the box was lacking.
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The results (Table 6) showed little variability across the patients,
with all patients showing no or only a minor degree of impairment.
Table 7 summarises the results from the design exclusion
assessment.
It is important to note that the levels of exclusion calculated for
each of the use scenarios are based solely on users with functional
impairments. They do not include users with learning difficulties,
as they are not typically classified as disabled under the ONS defi-
nitions. As such, the estimated levels of exclusion can be considered
to be conservative since the ONS data are based on self-reporting
(which in itself is most often conservative) and represents only
those living in private homes and with functional impairments.
Furthermore, it is likely that a higher proportion of methotrexate
patients would be excluded from using packaging, since they are
likely to have more severe strength and dexterity problems than
those in the general data from which the results were derived.
5. Discussion
For both sets of interviews, and the observations with patients,
a degree of caution is needed in interpreting the results. The
research was carried out approximately four years after a major
incident involving inadvertent methotrexate overdose that had
occurred in the same geographical area. The report that followed
this incident (CHA, 2000) strongly influenced local practice towards
methotrexate across community and hospital-based care. As such,
it is possible that practice was better in this area than in others less
local to this incident. Given the limited sample size, the degree to
which the results can be generalised to the wider population of
methotrexate users is also restricted.
Regarding the assessment of strength-related functions (e.g.
opening CRCs), the severity of difficulties experienced by users in
this study may be greater than those for the average user of
methotrexate, particularly given the fact that almost all of the
participants were females, who have been found to be nearly twice
as likely than males to be unable to open containers (Atkin et al.,
1994).
Nevertheless, despite their high level of competence (as
assessed against the ONS data), patients experienced a number of
problems, which can broadly be divided into two types of difficulty.
5.1. Difficulties associated with correct identification
Various problems were identified which relate to correct iden-
tification of medicines. The similarity in appearance between
containers of different medicines, and methotrexate and folic acid
tablets, could lead to mix-ups between medicines. With two of the
12 patients actually confusing methotrexate with folic acid (both
patients were experienced users since both had each been taking
methotrexate for several years without interruption), the study
suggests that mix-ups may not be uncommon amongst the wider
population of methotrexate users. Due to their similarity in size,
colour and shape, it is perhaps particularly unfortunate that
methotrexate and folic acid tablets – as they are designed currently
– are both typically used in conjunction with each other. Through
additional studies, further clarification would be beneficial on the
scale of mix-ups between a broader set of medicines due to simi-
larity of appearance, to determine whether it would be helpful to
patients and other stakeholders to change the design of either
methotrexate or folic acid tablets and/or packaging or combina-
tions of other medicines.
The researchers are not aware of published evidence to confirm
or deny an increased risk of mix-ups between medicines as a result
of concurrent use of many different drugs. Nevertheless, with an
average of approximately eight prescription-only medicines, it is
possible that the risk of mix-ups was increased for the patients in
this study. It seems logical that the storage of all medicines together
in a single container may also contribute to the risk, although there
appears to be a similar lack of evidence in the wider literature to
support or refute this.
Table 4
An excerpt from the HAZOP results.
Function Deviation Risk
component




card out of date
L 2 When attending a blood test, patients are expected to bring their blood record card with them. It may be
easy to forget to bring this card, hence it could easily become out of date.
I 2 Out of date cards can make it difficult for the nurse to identify what constitutes a normal blood test result
for that patient. Test results are a useful early warning system of the suitability of the patient’s medication
practices. Failure to spot trends could lead to a deteriorating condition being missed. Impact of deviation
could be anything from low to high, depending on patient’s dosing compliance. Average¼medium.
D 1 Patients are seen regularly, so good detectability.
RPN 4 MEDIUM RISK
Table 5
An excerpt from the risky scenarios study results.
Scenario L I D RPN
1. (At Home) Wrong dose administered (e.g. if 10 mg tablet is used instead of 2.5 mg tablet). This may happen for example when the number of
tablets (e.g. 15 mg¼ 6# 2.5 mg) is changed (e.g. 15 mg¼ 1#10 mgþ 2# 2.5 mg) and the patient becomes confused between the 2.5 mg and
the 10 mg tablets (e.g. takes 6# 10 mg).
3 3 3 9
2. (At Home) Folic Acid (FA) vs. Methotrexate (M) – similarity in FA and M packaging and/or appearance of FA and M tablet and confusion results,
leading to the ingestion of the wrong number of tablets.
3 3 3 9
3. (In Community Pharmacy) Pharmacy picking error – e.g. Methotrexate 2.5 mg stored next to Methotrexate 10 mg and wrong tablets are dispensed,
leading to potential for 4x overdose (would probably only occur with bottle confusion).
3 3 1 9
4. (In Community Pharmacy) Pharmacist only writes total dose of Methotrexate, not number of tablets to take, which could lead to an overdose if the
strength of the tablets has changed.
3 3 1 9
5. (At GP Practice) GP/receptionist fails to notice changed prescription request from patient (e.g. patient writes on the prescription request that the
dose has changed perhaps after seeing the specialist at the hospital, but GP authorises old prescription as he/she doesn’t see the note). Could
result in too high a dose being taken if patient’s dose is needed to be lowered.
2 3 1 6
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Whilst there appears to be general agreement in the NHS that
there can be no substitute for reading the label (DH, 2004; MCA,
2003), users of medicines may find other design features to be
helpful when selecting medicines, such as the judicious use of
colour, as recommended in the Medicines and Healthcare Products
Regulatory Agency’s document, Best practice guidance on the
labelling and packaging of medicines (MCA, 2003). The research in
this paper also suggests that clear instructions should be provided
by the manufacturer on how to open the container, as demon-
strated by the problems experienced by patients who attempted to
open the double-walled squeeze & turn closure.
5.2. Difficulties associated with ease of opening containers
Given the length of time taken required to open their medicines
containers and the proportion of methotrexate users who were
unable to do this at all, it can be concluded that patients experi-
enced sizeable difficulties when trying to access their medicines,
whether packaged in blister packs or containers with CRCs. These
problems frequently caused considerable frustration and, in some
cases, notable pain. Underscoring this problem, several patients
found it necessary to receive assistance in accessing their medi-
cines. The design exclusion exercise provided further evidence of
the scale of the problem that patients are likely to face when trying
to access their medicines.
Nearly half of the methotrexate users were unable or were
unwilling to attempt to open the more difficult of the two push-
down-&-turn CRCs, and almost all patients commented without
prompting by the researchers on the difficulty of using such
containers. A similar proportion of users were unable to open the
squeeze & turn CRC. Although the problems with using blister
packs were less severe (all patients eventually managed to extract
the tablets) nearly half of the patients experienced at least a small
degree of difficulty, which produced frustration and delay as they
grappled with the packaging.
The design exclusion assessments indicate that approximately 1
in 5 medicines users aged 75þ are unable to open push-down-
&-turn CRCs. This figure cannot easily be compared to the observed
results withmethotrexate users, due to the differences between the
two populations (the study population consisted of a small sample
of mostly female users of a younger average age, with specific
medical conditions). However, both figures show that a significant
proportion of users would be unable to access their medicines if
using such containers. Whilst the level of exclusion for users of
blister packs is predicted to be lower, it is still significant, and the
design exclusion assessments do not show the considerable
amount of effort needed to access medicines in such containers, as
suggested by the observed results with methotrexate users.
The design exclusion assessments also show how the propor-
tion of excluded users increases considerably when the variety of
tasks necessary to use medicines are combined. The figures
suggest that around one in four patients are unable to access their
medicines, either in blister packs or in bottles with push-down-
&-turn CRCs.
For blister pack use, the results indicate that it may be beneficial
to educate the patient in suitable technique in replacing the
medicine, since using the right technique can make this task
considerably easier. Advice on suitable strategies might be given to
patients by the manufacturer or other stakeholders such as phar-
macists or specialist nurses. Alternatively, manufacturers could
consider ensuring that there is sufficient room for all components
within a blister pack (i.e. PIL and blister strips) to be inserted easily
by patients with low dexterity. ‘‘Pill popping’’ devices, which can
improve the ease of removal of tablets from blister packs, may also
be of benefit to some patients (Mawle, 2003).
Risks to patients and possibly children may arise due to the
‘‘coping strategies’’ that patients developed as a result of these
problems. Regarding the risk to patients, although no actual errors
were identified during the interviews and observations, it is
possible that they could take the wrong medicine due to the
practice of transferring medicines from one container into another.
Incorrect labelling on the new container could, for instance, result
in confusion for a carer or healthcare professional if it became
necessary, at some point in the future, to administer the tablets to
the patient. Indeed, the researchers are aware of incidents when
exactly this scenario has occurred after patients have been
admitted into hospital, and care has been transferred to healthcare
professionals who are unaware of the medicines repackaging.
Such a scenario may not be uncommon: since this research was
completed, a study of 103 patients with inflammatory arthritis has
been published (Hughes et al., 2008). The authors found that the
majority of patients were unable to open their medicines
containers without assistance from another person or a device used
for opening containers. They also report a similar proportion of
subjects (31 in 103, versus 3 in 12 in this study) who routinely
decanted their medicines from the original pack into other
containers because of difficulties in opening.
Table 7
Results of the design exclusion exercise (sub-tasks are denoted in italics).








Reading and understanding instructions 2.6 6.5
Picking up a small tablet 3.2 12.6
Opening a blister pack 2.7 9.3
Opening a bottle with a CRC 6.5 20.3
Using a blister pack (tasks¼ reading and
understanding instructions, opening blister
pack and picking up a small tablet)
6.3 22.7
Using a bottle with a CRC (tasks¼ reading and
understanding instructions, opening bottle
with a CRC and picking up a small tablet)
9.1 29.8
Table 6
A summary of the assessment of patients’ abilities.
Assessment Average result Standard
deviation
Reach and stretch (maximum possible
impairment score¼ 9.5)
1.0 (equivalent to having difficulty in putting one arm behind back to put on jacket/or putting one arm
out in front or up to head)
1.7
Dexterity (maximum possible impairment
score¼ 10.5)
0.9 (equivalent to having difficulty picking up a small object such as a safety pin with one hand/being
unable to carry a pint of milk with one hand/having difficulty in tying bow in laces or string)
1.0
Seeing (maximum possible impairment
score¼ 12.0)
0.2 (equivalent to full ability) 0.4
Intelligence (maximum possible
impairment score¼ 13.0)
0.0 (equivalent to full ability) 0.2
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In Hughes’ paper the authors examined the preferences of
patients over seven different types of medicines container. The
container of highest preference was squat-shaped, with a large
diameter bottle and closure, which facilitated gripping and turning,
and a wide neck which eased removal of the tablets. This may
provides a useful indication on the shape and size of suitable
containers of the future, particularly when considering the fact that
the evaluation of a standard bottle (identical to that evaluated in
this study) received the lowest preference score on account of the
difficulty by patients in performing a push-down-and-turn
movement.
Regarding the risks to children, several patients declared that
they did not fully re-close the child-resistant tops, meaning that the
purpose of the CRC was defeated. For patients, further problems
could arise due to the potential of contamination in bottles that
have been used for a very long period of time, or for single bottles
that have contained a variety of medicines over the years.
5.3. Other issues
The study’s findings, particularly through the results of the risk
analyses, provide evidence that the healthcare system cannot be
completely relied upon to support the safe use of methotrexate by
patients. Since the packaging and labelling of medicines can also
fulfil functions that the healthcare system is supposed to provide
(e.g. providing clear dosing instructions), their design may be
especially important in supporting safe healthcare, since patients
may rely upon them even more than they might otherwise. For
example, failures in the blood test monitoring process mean that it
is even more important for patients to take the right dose of their
methotrexate, through following the instructions on the labelling.
Similarly, the frequent failure to provide PILs to patients means that
the labelling may be the only source of information for patients,
and hence is doubly important.
6. Development of design concepts
6.1. Development of requirements
Before asking the professional designers to develop design
concepts, a number of design requirements were formed by the
research team. Based on a review of the problems identified during
the earlier stages of the research and the ‘‘five rights’’ of medicines
use (right patient, right drug, right dose, right route, and right
time), a very simple guiding principle was produced by the research
team for the development of the requirements for methotrexate
packaging and labelling:
Design concepts must help the patient to take
the right dose of the right drug at the right time.
Based on the problematic areas identified, more specific design
requirements were next developed by the research team:
1) Packaging and labelling concepts should ensure that the right
dosing action is clear.
2) Packaging and labelling should be distinctive.
3) Packaging should be accessible, meaning that it should exclude
as few users as possible.
At the designworkshop, to encourage further thought about the
design problem, the designers were asked to develop their own
design requirements without researcher input, based on what they
had learned through the presentation. Whilst the precise words
were different, the designers produced requirements that were
fundamentally identical to those above, a result which was judged
as an independent vote of confidence in their suitability.
To avoid constraining ideas at this stage, and to ensure
simplicity during the limited time available with the design
consultants, a number of other design requirements were omitted
from the brainstorming exercise. These included cost, child-resis-
tance, maintaining tablet integrity and efficacy (including protec-
tion from light, heat and moisture), ensuring minimum handling of
the tablet due to its cytotoxic nature and flexibility of supply due to
the likelihood of dosing change.
6.2. Development of design concepts
The brainstorming sessionwas divided into four sections: Tablet
design, Packaging design, Labelling design and Potential Action by
healthcare professionals/healthcare system-level design.
This process produced approximately 100 initial concepts (Ward
et al., 2004). A review by the researchers, against the initial
requirements and general constraints of practicality, reduced this
list to a total of 36 design concepts, such as:
! Increase the size of methotrexate screw tops (to increase tor-
que for opening).
! Provide patients with each week’s dose in a separate container.
! Increase the size of methotrexate tablets to facilitate handling.
! Print on both sides of the blister strip.
! Provide only four weeks’ supply of methotrexate for each
prescription.
! Inform patients of the option to receive a standard closure.
The design company developed five further design concepts, as
detailed below:
A. A distinctive shaped blister, linked to the tablet’s shape. One
week’s prescription is dispensed from bulk at the pharmacy
and added to a preformed blister container. The blister is sealed
and labelled at the pharmacy. The label is tailored to meet
individual patient needs.
B. One month’s supply of tablets is stacked as four individual
units, one for each week. Individual pots are filled and labelled
at the pharmacy. Each pot can be filled with water, to assist the
patient to take the dose.
C. Individual wallets are filled and labelled at the pharmacy. The
label has a self adhesive peel-off strip which can be attached to
a record card and returned to the pharmacy at the end of
treatment. This has easy-open features, combined with
a tamper-evident label.
D. A blister pack dispenser which dispenses and labels patient-
specific prescriptions from a bulk reel of blisters. Packs are
supplied in four parallel strips. Each strip provides one week’s
supply.
E. A reusable intelligent dispenser which alerts the patient to
when the tablets need to be taken. Tablets are containedwithin
a tamper proof carousel which is filled and labelled at the
pharmacy. Bar code details are read by the dispenser. The
patient depresses an actuator to deliver tablets, when
the indicator light is illuminated. A safety interlock prevents
the dispenser from being opened until the prescription is
finished or prevents tablets being dispensed until a desired
time interval has elapsed. Electronics within the dispenser
store compliance information which can be later downloaded
by a physician.
At the end of the research, the study’s findings and the design
concepts were presented by the researchers to the manufacturers
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of methotrexate. These were received with great interest. It was
emphasised to the manufacturers that all concepts were yet to be
evaluated formally and so must not be regarded as solutions.
7. Developments since the research was completed
Since the research was carried out, the UKs National Patient
Safety Agency has produced a number of publications to improve
the safe use of oral methotrexate across the healthcare system.
These include the introduction of guidance on packaging design
(NPSA, 2007a), aimed particularly at designers, and guidance for
healthcare practitioners on good design practice for dispensed
products (NPSA, 2007b), which also provides information on the
availability of various aids to help patients use their medicines. At
more of a ‘‘systems’’ level, the NPSA has also published guidance
on the design of the dispensing environment in pharmacies
(NPSA, 2007c).
Also at a systems level, the NPSA has published a package of
measures (NPSA, 2006), which includes information for patients on
safe practice with methotrexate, a blood monitoring and dosage
record booklet for patients, guidance for practitioners and
a requirements specification for the development of safer infor-
mation technology systems. The authors believe that the combi-
nation of these measures address well the risks identified by this
research. All NPSA’s documents can be downloaded for free from
their Web site.
From the perspective of the pharmaceutical industry, the shape
of the 10 mg tablet, which was originally very similar in appearance
to the 2.5 mg tablet, has been modified to aid discrimination
between the two strengths, although controversy remains about
the suitability of providing 10 mg tablets at all and some healthcare
regions in the UK do not prescribe these tablets as a matter of
course.
Several manufacturers now supply methotrexate in the UK. Two
notable changes since this study began are that at least one
manufacturer now provides methotrexate in packs of 24 (consist-
ing of two blister strips, each with two rows of six tablets), rather
than the usual 28 tablets (also two blister strips, but with two rows
of seven tablets). This may be to try to help distance the patient
from the idea that seven tablets in a row might indicate one to be
taken per day. Another manufacturer provides methotrexate in
a small pot, very similar in size and shape to a camera film canister.
However, most manufacturers provide bulk packs of 100 metho-
trexate tablets, for pharmacists to re-pack into generic pharmacy
bottles, meaning that mix-ups may still occur between metho-
trexate and other medicines. The UK’s National Patient Safety
Agency continues to work with the pharmaceutical industry to
develop safer and more user-friendly packaging.
8. Conclusions
Medication plays an increasingly important role in society, and
its packaging and labelling provide a vital function in supporting
safe use. Evidence from reports of medication errors has shown
that poor packaging and labelling design results in a variety of
problems to users of medicines, ranging from inconvenience to
serious harm and even death. This study examines the use of
methotrexate in tablet form and provides further, graphic evidence
of these problems and an indication of their scale for users of
methotrexate.
To help the findings from this work to be systems-based, the
research investigated both methotrexate users’ practice and the
nature of the healthcare system which supports the use of meth-
otrexate. The research also utilised a range of research methods.
However, given the size of the study, the results – including the
recommendations – need to be treated with caution. Further work
is strongly recommended to clarify the scale and nature of prob-
lems experienced by patients using methotrexate, and for users of
medicines in general.
Nevertheless, the results demonstrate strongly that for some
methotrexate users, the design of the packaging and labelling is so
unsuitable that they are completely unable to access their medi-
cines without the provision of outside assistance. The design
exclusion assessment carried out during this research also supports
this finding. An indirect result of such user-unfriendly design is that
methotrexate patients adopt a variety of ‘‘coping strategies’’, which
may also lead to further decreases in their safety and for the safety
of third parties such as children.
Whilst the findings relate specifically to users of methotrexate,
who may experience particular difficulties in accessing medicines
due to their medical conditions, other research shows that older
users also experience similar difficulties. The findings and the
recommendations from this study may also, therefore, be broadly
applicable to medicines in general.
The study underscores the importance of not only good pack-
aging and labelling design but the design of the system that
supports the safe use of medication. As a result of this and other
related research, systems-wide changes have already been imple-
mented across the NHS. It is hoped that the results from this study
will continue to both motivate and inform the development of
more appropriate solutions for patients in the future, through
improved packaging design and through changes to the related
healthcare system.
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